Adults with acute lymphoblastic leukemia (ALL) who are 65 years of age or older, or who carry other serious health conditions, represent a population in which induction therapy must be considered in the context of individual tolerability.
This protocol covers the management of ALL in patients defined by older age (65 years and older) or by the presence of significant comorbidities. These factors influence which components of induction therapy are appropriate and at what intensity.
Induction chemotherapy — drawing on the same class of agents used in younger adults — may be considered for this population, with the regimen potentially modified to reflect patient-specific tolerability. The full structured protocol details which components apply, how they may be adjusted, and under what conditions.
Adults who are age 65 and older, or those who have other serious health conditions, may receive the same drugs mentioned above for induction, although the doses of drugs may be reduced and/or the anthracycline may be removed from the regimen.
View source ↗